New data strengthen profile for Pharmacyclics' novel blood cancer drug
This article was originally published in Scrip
The clinical profile of Pharmacyclics' novel anticancer PCI-32765 – licensed last week to Janssen for an upfront payment of $150 million – has been boosted from data presented at the American Society of Hematology meeting in San Diego.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.